This review article outlines the evidence that 24 h blood pressure (BP) measurements are particularly important predictors of adverse cardiovascular outcome. In turn, there is supportive evidence from a range of studies that 24 h BP control should be an integral part of the antihypertensive drug treatment strategy. Furthermore, since not all once daily antihypertensive agents can provide such 24 h control, there is a requirement for careful drug (and/or dosage) selection. Although the clinic (office) BP continues to be the standard measurement by which hypertension is diagnosed and treatment monitored, there is now clear evidence of the superiority of 24 h BP assessments. Although there are not yet prospective, outcome clinical trails which have relied upon 24 h BP values there is clear evidence that 24 h BP values correlate much more closely than conventional clinic BP values with measurements such as left ventricular hypertrophy, cerebral vascular damage (lacunar infarcts), renal damage (microalbuminuria) and vascular damage (carotid artery intima media thickness). In turn, there is evidence that during drug treatment, when achieved clinic blood pressures appear to be comparable, there is improved outcome in those patients whose 24 h BP values are significantly lower. Not all antihypertensive drugs are equivalent, however, in their abilities to reduce 24 h BP and the clinician needs to be aware of possible shortcomings when considering the choice of drug. In this respect, intrinsically long-acting agents are best equipped to provide sustained and consistent BP control throughout 24 h.
Introduction
The evidence identifying the relationship between hypertension and cardiovascular disease, the benefits of antihypertensive drug treatment and even the shortcomings of some of the current treatment strategies have generally been derived from studies using conventional sphygmomanometry in the clinic (office) setting. While the clinic blood pressure (BP) measurement continues to dominate routine clinical practice, there is an ever-increasing awareness of the relevance of 24-h BP measurement and 24-h BP control. This should not be taken to imply that 24-h ambulatory BP monitoring (or multiple home BP recordings) should now be incorporated into routine clinical practice but, instead, it is a recommendation that information derived from 24-h BP studies should be used to refine our approaches to not only the definition of hypertension but also, and more importantly, the implementation of optimal types of antihypertensive drug treatment.
The conventional clinic BP can be likened to a 'snap-shot' photograph that captures a BP reading at a particular time, typically at some time in the regular working day between 09:00 and 18:00 h. On the basis of this isolated snap-shot, even with repeat measurements over a period of time and under standardised conditions, the patient is classified either as 'hypertensive' or 'normotensive'. Correspondingly, once treatment has been started, the same snap-shot clinic BP reading will be used to define whether the patient is 'well controlled' or 'uncontrolled'. Since the BP profile of any individual will vary intrinsically throughout 24 h, most notably with a reduction during overnight sleep, and also in response to changes in the levels of physical and mental activity, it is remarkable that the use of the 'snap-shot' BP measurement has remained the accepted clinical method of assessing the hyperten-sive patient, and monitoring a treatment strategy which may well last for 20 years and more.
24-h BP and cardiovascular risk
In the same way that the duration of uncontrolled hypertension over a period of years will determine the extent and severity of cardiovascular target organ damage, there is an obvious parallel that the period of time that BP remains elevated during any given 24 h will determine the extent and severity of cardiovascular target organ damage. Thus, a BP 'load' that is created by frequently recurring hypertensive values throughout any 24-h period will lead to some degree of cardiovascular target organ damage. This concept of a 24-h BP load is illustrated in Figure 1 . White et al. 6 In turn, the relationship between BP load and cardiovascular target organ damage is illustrated in Figure 2 , in which the target organ damage is represented by the left ventricular (LV) mass index. It is immediately apparent that the conventional clinic BP measurement does not correlate with the LV mass index. In contrast, where the BP load on the cardiovascular system is calculated as an elevated daytime BP, an elevated nighttime BP or an elevated 24 h BP, there are clear and statistically significant correlations. A number of different studies have similarly explored the relationship between 24-h BP measurements and the development of different types of hypertensive cardiovascular target organ damage. Invariably, the correlations derived from the 24-h BP measurements have proved superior to those of the conventional clinic BP measurement irrespective of the chosen index of target organ damage (see Table 1 ).
Cardiovascular risk and 24-h BP control
The importance of 24-h BP in the sense of BP control throughout the whole 24-h is also being increasingly reported. For example, in the sample study correlations were sought between the LV mass index and three different types of BP assessment: home BP measurements, conventional clinic BP measurements and 24-h BP measurements. 1 Prior to treatment, there was no correlation between the LV mass index and the BP values derived from the home or clinic BP measurements (Table 2) . Instead there was a statistically significant correlation only with the 24-h BP assessment. After 1 year of treatment leading to a significant reduction in BP and LV mass index, the reduction in LV mass index was again correlated with the reduction in 24-h BP but there were no statistically significant correlations with the changes in either home or clinic blood pressure ( Table 2) . A further illustration of the importance of 24-h BP control is seen in a study of patients with refractory hypertension who were already receiving treatment with a thiazide diuretic and at least two additional antihypertensive drugs. These 86 patients appeared to be carrying similar cardiovascular risk by virtue of inadequately controlled hypertension and clinic diastolic BP values consistently above 95 mmHg. However, when the group of patients was sub-divided according to their 24-h BP averages, there was a clear difference in the cardiovascular event rate (Table 3) . Even though all of these patients appeared to be similarly at risk with clinic diastolic BP above 95 mmHg, the group with an average 24-h diastolic BP of less than 88 mmHg developed 2.2 cardiovascular events per 100 patient years whereas the group with an average above 97 mmHg developed 13.8 cardiovascular events per 100 patient years. This not only illustrates the importance of the level of BP throughout 24-h but it also highlights the shortcomings of the conventional clinic BP measurement.
Antihypertensive drug treatment and 24-h BP control
One of the most basic concepts for the conventional clinic BP measurement is that it provides information about the effectiveness of a particular antihypertensive drug treatment. Once again, however, the assumption is made that a 'snap-shot' BP assessment provides information about the effectiveness of the drug treatment throughout 24-h. If the drug effect is variable, and especially if the BP lowering effect is relatively short lived, there is a clear danger that the effectiveness of the drug treatment might be overestimated. This would be particularly true in the case of drug with a relatively rapid onset of action and a relatively short duration of action (perhaps only 8-12 h) with the BP measured, as is customary, during the working day. The potential problems are illustrated in Figure 3 from a study by Stokes et al. 3 It is readily apparent in Figure 3 (upper panel) that a conventional clinic BP measurement taken at approximately 11:00 h would show an apparently excessive BP reduction with a systolic BP of o100 mmHg. The likeliest clinical decision based on this measurement would be a reduction in dosage and a review of the patient shortly thereafter. With such a strategy the patient might be reviewed 1 or 2 weeks later (Figure 3-lower panel) , and at approximately 11:00 h it can be seen that BP control now appears to be optimal with a value around 130 mmHg systolic BP. Unfortunately, it is also apparent that for the greater part of the rest of the 12-h period there is sub-optimal BP control with systolic BP values around 170 mmHg and diastolic BP values around 100-110 mmHg. Thus, drugs with variable efficacy can create practical problems for the clinician.
This variability in antihypertensive effect is seen with many drugs and even with some agents that are widely presumed to be reliable, once-daily agents. For example in an analysis of enalapril administered either as 20 mg once daily or 10 mg twice daily, it can readily be seen that the antihypertensive effect is more consistently maintained throughout 24-h 
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when the drug is administered on a twice-daily basis compared to the usually recommended once-daily dosing schedule (Figure 4 ). 4 
24-h BP control and compliance with treatment
In the management of hypertension, noncompliance and poor compliance are well-recognised practical problems. The question then arises as to how the duration of action of a particular antihypertensive drug might cope with, or compensate for, irregular patient compliance and occasional missed dosages.
There is a further consideration regarding the differences between intrinsically long-acting drugs and those agents that are dependent upon formulation technology to extend their effectiveness. The potential differences between an intrinsically longacting drug and a modified release formulation are schematically illustrated in Figure 5 . In terms of the plasma drug concentration-time profiles, it can be seen that the intrinsically long-acting agent will maintain drug levels even when the patient has failed to take the next daily dose. In contrast, with the modified release formulation there is a very rapid decline in drug concentrations when a dose is omitted because the formulation has exhausted its drug supply and the intrinsically short-acting pharmacokinetic characteristics of the drug are exposed. This type of comparison was specifically explored in a study comparing amlodipine with nifedipine GITS. 5 In pharmacokinetic terms, there is little to choose between these two agents across 24-h when full compliance is obtained. In turn, this translates to very similar levels of BP control with an average diastolic BP of 87.3 on amlodipine compared to 88.5 mmHg on nifedipine GITS. However, in the face of one missed dose, BP control was maintained at 87.7 mmHg with amlodipine whereas it had significantly deteriorated to 89.4 with nifedipine GITS, and there was a further deterioration after two missed doses with the average diastolic BP at 93.5 mmHg after the missed doses of nifedipine GITS whereas diastolic BP control was still maintained at 87.8 mmHg after two missed doses of amlodipine.
This technique of assessing the BP response to missed dosages might usefully be incorporated into early clinical trial designs because it permits a clear exploration of the duration of action of a particular agent.
Conclusions
There is an increasing volume of evidence indicating that the level of BP throughout 24-h is superior to the conventional clinic BP measurement in predicting the development of cardiovascular target organ damage. There is corresponding information to show that 24-h BP control leads to better outcomes for treated hypertensive patients. It is a straightforward concept, therefore, to apply this information to the choice of antihypertensive drug treatments to select agents that are best suited to the provision of effective 24-h blood pressure lowering. There also are potential, additional advantages in relation to noncompliance if intrinsically longacting agents are chosen in preference to those reliant upon formulation technology. Thus, without any major changes to conventional clinical practice (which continues to rely on the conventional clinic BP measurement), it should be possible to identify agents within each of the major drug classes that are best suited to the provision of 24-h BP control. 
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